Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating restated by research analysts at Piper Jaffray Companies in a report released on Thursday. They presently have a $24.00 price target on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price target indicates a potential upside of 39.45% from the stock’s previous close.

A number of other equities analysts also recently commented on COLL. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Monday, November 13th. HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, November 8th. Needham & Company LLC reissued a “buy” rating and set a $25.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Finally, Jefferies Group reissued a “buy” rating and set a $15.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Collegium Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $23.50.

Collegium Pharmaceutical (NASDAQ:COLL) opened at $17.21 on Thursday. Collegium Pharmaceutical has a 1 year low of $7.37 and a 1 year high of $20.92.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.28. The company had revenue of $11.95 million for the quarter, compared to analyst estimates of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The firm’s revenue for the quarter was up 2814.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.13) earnings per share. analysts anticipate that Collegium Pharmaceutical will post -2.56 earnings per share for the current year.

In related news, CEO Michael Thomas Heffernan sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $15.53, for a total transaction of $776,500.00. Following the transaction, the chief executive officer now directly owns 558,987 shares of the company’s stock, valued at $8,681,068.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Alison B. Fleming sold 4,029 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $17.00, for a total transaction of $68,493.00. Following the transaction, the chief technology officer now directly owns 28,513 shares in the company, valued at $484,721. The disclosure for this sale can be found here. Over the last quarter, insiders sold 58,630 shares of company stock worth $924,360. 25.76% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of COLL. Tocqueville Asset Management L.P. raised its position in shares of Collegium Pharmaceutical by 11.6% in the 4th quarter. Tocqueville Asset Management L.P. now owns 55,800 shares of the specialty pharmaceutical company’s stock valued at $1,535,000 after acquiring an additional 5,800 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Collegium Pharmaceutical during the first quarter worth approximately $238,000. Vanguard Group Inc. grew its stake in Collegium Pharmaceutical by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock valued at $8,113,000 after purchasing an additional 58,398 shares during the period. Teton Advisors Inc. purchased a new position in shares of Collegium Pharmaceutical during the 3rd quarter valued at $283,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Collegium Pharmaceutical by 60.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 104,961 shares of the specialty pharmaceutical company’s stock valued at $1,313,000 after buying an additional 39,656 shares during the last quarter. Institutional investors and hedge funds own 79.98% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Piper Jaffray Companies Reaffirms Buy Rating for Collegium Pharmaceutical (COLL)” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/07/piper-jaffray-companies-reaffirms-buy-rating-for-collegium-pharmaceutical-coll.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.